Supporting Patients in Bladder Cancer Surgery: Comparing Two Techniques
NCT06703476 · RecruitingThis study looks at two common surgical techniques used during surgery for bladder cancer, called radical cystectomy. The goal is to see if these techniques affect how long patients stay in the hospital and the risk of infections after surgery. One technique involves using a ureteral stent, a small tube that helps drain urine but may increase the chance of infections. The other involves using a medication called alvimopan, which helps the bowel function return after surgery. Doctors will assign participants to receive either of these treatments based on chance if they are unsure of the best approach.
Locations and contact
This trial is running at 7 locations in the United States. All of them are currently recruiting.
United States7 locations · 7 recruiting
- Memorial Sloan Kettering at Basking Ridge (Consent Only)Basking Ridge, New JerseyRecruiting
- Memorial Sloan Kettering Bergen (Consent Only)Montvale, New JerseyRecruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)New York, New YorkRecruiting
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New JerseyRecruiting
- Memorial Sloan Kettering Nassau (Consent Only)Rockville Centre, New YorkRecruiting
- Memorial Sloan Kettering Suffolk-Commack (Consent Only)Commack, New YorkRecruiting
- Memorial Sloan Kettering Westchester (Consent Only)Harrison, New YorkRecruiting
Who can join
Anyone aged 21 or older who is scheduled for surgery to treat bladder cancer can join. This trial is open to both men and women. Patients on long-term opioid therapy cannot take alvimopan and will not be eligible for that part of the trial. The trial team will confirm who can participate.
What happens during the trial
Participants will be randomly assigned to one of two groups. In one group, some will receive a ureteral stent placed during surgery, while others will not. In the second group, some participants will receive alvimopan before and after surgery, while others will not receive it. This means everyone gets one of the treatments, but which treatment they get is decided by chance.
The trial team
The trial is sponsored by Memorial Sloan Kettering Cancer Center. The lead doctor is Dr. Alvin Goh, who is a principal investigator at the center.
Important dates
The trial started on November 21, 2024, and is expected to finish in November 2028. It is currently enrolling new participants.
Additional information
The trial's ID number is NCT06703476. This is a Phase 3 trial, which means it is looking at how well the treatments work and how safe they are. The study is regulated by the FDA and aims to include about 530 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →